Pharmaceutical
Filter News
Found 55,974 articles
-
Sosei Heptares and Biohaven Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio
12/1/2020
Sosei Group Corporation announces it has entered into a global collaboration and license agreement with Biohaven Pharmaceutical Holding Company Ltd..
-
Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Class A Common Stock - Dec 01, 2020
12/1/2020
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced the launch of a proposed underwritten public offering by the Company of 2,000,000 shares of its Class A common stock pursuant to an existing shelf registration statement.
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Dec 01, 2020
12/1/2020
Cytokinetics, Incorporated announced that on November 30, 2020 it granted stock options to purchase an aggregate of 62,850 shares of common stock to six new employees whose employment commenced in November 2020 as a material inducement to their employment.
-
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Dec 01, 2020
12/1/2020
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, announced that on November 30, 2020, the Company granted stock options and restricted stock units to one new employee of the Company.
-
atbtherapeutics Initiates Agreement With iBio CDMO to Manufacture Game-changer atbodies to Better Treat Cancer
12/1/2020
atbtherapeutics, a pioneering biopharmaceutical company building an oncology pipeline using its antibody–toxin-bioengineered “atbody”, announces that it has entered a long-term manufacturing agreement with iBio CDMO, a global leader in plant-based biologics manufacturing located in the US.
-
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 01, 2020
12/1/2020
X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, announced that, on November 30, 2020, the Compensation Committee of X4’s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.
-
Amit Singhi joins Humanetics Group as Chief Financial Officer (CFO)
12/1/2020
HUMANETICS GROUP, the global safety, sensor and precision engineering business, announced that Amit Singhi has joined the Humanetics Group as Chief Financial Officer reporting to Chris O’Connor, President and CEO.
-
TearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of GlaucomaPrepared to file an IND in mid-2021 via the 505(b)(2) NDA pathway
12/1/2020
TearClear, an emerging ophthalmic pharmaceutical company, announced successful completion of pre-IND meeting with the U.S. Food and Drug Administration regarding the development plan for the preservative free multi-dose delivery of a proprietary Latanoprost formulation, including the clinical study design for the registration study.
-
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 01, 2020
12/1/2020
Dicerna Pharmaceuticals, Inc., a leading developer of investigational ribonucleic acid interference therapeutics, announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 30,575 shares of common stock and 8,750 restricted stock units to be distributed among six new employees with a grant date of Dec. 1, 2020.
-
Thomas Biegi Joins MorphoSys As Head of Corporate Communications
12/1/2020
MorphoSys Prime Standard Segment; MDAX & TecDAX; announced that Thomas Biegi joins the company as Vice President, Head of Corporate Communications, effective December 1, 2020.
-
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock - Dec 01, 2020
12/1/2020
Avid Bioservices, Inc. announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock.
-
Noema Pharma raises CHF54 million in Series A financing round led by Sofinnova Partners and Polaris Partners
12/1/2020
Strong participation from international syndicate of investors, including Gilde Healthcare, Invus and BioMed Partners
-
Another clinical study could confirm the 90% efficacy data that stemmed from accidental use of a half-dose in an arm of its Phase III trial.
-
The FDA approval was based on results from the largest studies conducted to date in obesity associated with POMC, PCSK1 or LEPR deficiency.
-
The end of November and beginning of December is marked by several PDUFA dates at the U.S. Food and Drug Administration (FDA). Here’s a look.
-
Clinical Catch-Up: November 23-27
11/30/2020
As the U.S. went into its Thanksgiving holiday week, clinical trial news was quieter than usual, although there was a lot of important news on the COVID-19 vaccine front. Here’s a look. -
Lannett Pays Off, In Full, Remaining Term A Loans
11/30/2020
Lannett Company, Inc. announced that the company used a portion of its existing cash on hand to pay off, in full, the remaining $42 million outstanding balance of its Term A Loans.
-
Ascentage Pharma Enters into an Agreement with University of Michigan to obtain an exclusive license for a MDM2 Degrader using PROTAC Technology
11/30/2020
Ascentage Pharma announced it has entered into an agreement with the University of Michigan, through which the company may obtain the exclusive global rights to a MDM2 protein degrader developed using the Proteolysis-Targeting Chimeras technology.
-
PureTech to Host Virtual R&D Day for Investors on December 11, 2020
11/30/2020
PureTech management to share research and clinical strategies for leveraging leadership in the lymphatic system and related immunology with the potential to deliver highly differentiated medicines
-
Telix Pharmaceuticals Limited Acquires TheraPharm GmbH, Broadening Reach to Hematologic Cancers and Transplant Medicine
11/30/2020
Telix Pharmaceuticals Limited announces it has entered into an agreement with Scintec Diagnostics GmbH to acquire TheraPharm GmbH, a Swiss-German biotechnology company developing innovative diagnostic and therapeutic solutions in the field of hematology.